Compare drug alternatives

Braftovi ® Alternatives

Braftovi ®(Encorafenib)
Tafinlar + Mekinist ®(Dabrafenib)
Prescription Only
Braftovi (encorafenib) is an oral medication that inhibits kinases and is utilized in combination with other drugs to address certain forms of cancer. It is authorized for use in...
Prescription Only
Tafinlar is a specific cancer medication that disrupts the growth and dissemination of cancerous cells within the body. It's specifically employed for treating particular cancers...
Dosage & AdministrationDosage & Administration comparison data
Administration
Dosing
Latin Shorthand
Financial AssistanceFinancial Assistance comparison data
Out-Of-Pocket Costs With Copay Card
Annual Cap
Assistance Expiration
Generics
No lower-cost generic available
No lower-cost generic available
Physician AdvisoryPhysician Advisory comparison data
Adverse Reactions
Melanoma: Most common adverse reactions (≥25%) for BRAFTOVI, in combination with binimetinib, are fatigue, nausea, vomiting, abdominal pain, and arthralgia. (6.1) CRC: Most common adverse reactions (≥25%) for BRAFTOVI, in combination with cetuximab, are fatigue, nausea, diarrhea, dermatitis acneiform, abdominal pain, decreased appetite, arthralgia, and rash. (6.1) NSCLC: Most common adverse reactions (≥25%) for BRAFTOVI, in combination with binimetinib, are fatigue, nausea, diarrhea, musculoskeletal pain, vomiting, abdominal pain, visual impairment, constipation, dyspnea, rash, and cough.. Learn more.
Most common adverse reactions (≥ 20%) for TAFINLAR as a single agent are hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome. Most common adverse reactions (≥ 20%) for TAFINLAR in combination with trametinib include: • Unresectable or metastatic melanoma: pyrexia, rash, chills, headache, arthralgia, and cough. • Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache, rash, chills, diarrhea, vomiting, arthralgia, and myalgia. • NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea. • Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema. • Pediatric patients with solid tumors: pyrexia, rash, vomiting, fatigue, dry skin, cough, diarrhea, dermatitis acneiform, headache, abdominal pain, nausea, hemorrhage, constipation, and paronychia. • Pediatric patients with LGG: pyrexia, rash, headache, vomiting, musculoskeletal pain, fatigue, diarrhea, dry skin, nausea, hemorrhage, abdominal pain, and dermatitis acneiform. . Learn more.
Mechanism of Actions (MoA)
Special Populations
Popular Alternatives
    Relevant Resources
    Braftovi
    Tafinlar + Mekinist
    Other indicationsCompare drug alternatives